Nephros Stock Buy Hold or Sell Recommendation
| NEPH Stock | USD 1.51 0.01 0.67% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Nephros is 'Strong Sell'. The recommendation algorithm takes into account all of Nephros' available fundamental, technical, and predictive indicators you will find on this site.
Check out Nephros Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide. In addition, we conduct extensive research on individual companies such as Nephros and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Nephros |
Execute Nephros Buy or Sell Advice
The Nephros recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nephros. Macroaxis does not own or have any residual interests in Nephros or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nephros' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Nephros Trading Alerts and Improvement Suggestions
| Nephros generated a negative expected return over the last 90 days | |
| Nephros may become a speculative penny stock | |
| Nephros has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 14.24 M. Net Loss for the year was (1.57 M) with profit before overhead, payroll, taxes, and interest of 4.73 M. | |
| About 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from insidermonkey.com: Nephros, Inc. Q3 2024 Earnings Call Transcript |
Nephros Returns Distribution Density
The distribution of Nephros' historical returns is an attempt to chart the uncertainty of Nephros' future price movements. The chart of the probability distribution of Nephros daily returns describes the distribution of returns around its average expected value. We use Nephros price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Nephros returns is essential to provide solid investment advice for Nephros.
| Mean Return | -0.29 | Value At Risk | -4.09 | Potential Upside | 2.74 | Standard Deviation | 2.19 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Nephros historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Nephros Stock Institutional Investors
| Shares | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 13.8 K | Citadel Advisors Llc | 2024-06-30 | 11.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 10.8 K | Tower Research Capital Llc | 2024-06-30 | 3.7 K | Jpmorgan Chase & Co | 2024-06-30 | 222 | Bank Of America Corp | 2024-06-30 | 76.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Granite Investment Partners, Llc | 2024-09-30 | 0.0 | Goss Wealth Management Llc | 2024-06-30 | 0.0 | Wexford Capital Lp | 2024-06-30 | 3.6 M | Vanguard Group Inc | 2024-09-30 | 202 K |
Nephros Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| End Period Cash Flow | 4.2M | 8.2M | 7.0M | 3.6M | 4.3M | 2.7M | |
| Change In Cash | (415K) | 4.1M | (1.3M) | (3.3M) | 673K | 706.7K | |
| Free Cash Flow | (2.3M) | (7.1M) | (1.5M) | (3.4M) | 752K | 789.6K | |
| Depreciation | 200K | 208K | 252K | 351K | 214K | 402.1K | |
| Other Non Cash Items | (105K) | 97K | 321K | 2.3M | 306K | 290.7K | |
| Net Income | (3.2M) | (4.5M) | (3.9M) | (7.1M) | (1.6M) | (1.7M) | |
| Change To Inventory | (735K) | (2.8M) | 296K | 915K | 387K | 406.4K | |
| Net Borrowings | 131K | (647K) | (312K) | (264K) | (237.6K) | (225.7K) | |
| Change To Netincome | 1.2M | 1.2M | 562K | 1.6M | 1.4M | 1.0M | |
| Investments | (151K) | (239K) | (85K) | (137K) | (75K) | (78.8K) |
Nephros Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nephros or Household Durables sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nephros' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nephros stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.34 | |
β | Beta against Dow Jones | 0.37 | |
σ | Overall volatility | 2.22 | |
Ir | Information ratio | -0.18 |
Nephros Volatility Alert
Nephros exhibits very low volatility with skewness of -0.08 and kurtosis of 0.05. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Nephros' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Nephros' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Nephros Fundamentals Vs Peers
Comparing Nephros' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nephros' direct or indirect competition across all of the common fundamentals between Nephros and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nephros or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nephros' fundamental indicators could also be used in its relative valuation, which is a method of valuing Nephros by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nephros to competition |
| Fundamentals | Nephros | Peer Average |
| Return On Equity | -0.16 | -0.31 |
| Return On Asset | -0.0796 | -0.14 |
| Profit Margin | (0.09) % | (1.27) % |
| Operating Margin | (0.1) % | (5.51) % |
| Current Valuation | 15.8 M | 16.62 B |
| Shares Outstanding | 10.54 M | 571.82 M |
| Shares Owned By Insiders | 12.70 % | 10.09 % |
| Shares Owned By Institutions | 40.92 % | 39.21 % |
| Number Of Shares Shorted | 11.07 K | 4.71 M |
| Price To Earning | (4.51) X | 28.72 X |
| Price To Book | 2.05 X | 9.51 X |
| Price To Sales | 1.15 X | 11.42 X |
| Revenue | 14.24 M | 9.43 B |
| Gross Profit | 4.73 M | 27.38 B |
| EBITDA | (1.38 M) | 3.9 B |
| Net Income | (1.57 M) | 570.98 M |
| Cash And Equivalents | 4.18 M | 2.7 B |
| Cash Per Share | 0.41 X | 5.01 X |
| Total Debt | 1.84 M | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 5.27 X | 2.16 X |
| Book Value Per Share | 0.79 X | 1.93 K |
| Cash Flow From Operations | 827 K | 971.22 M |
| Short Ratio | 0.04 X | 4.00 X |
| Earnings Per Share | (0.09) X | 3.12 X |
| Target Price | 4.75 | |
| Number Of Employees | 31 | 18.84 K |
| Beta | 1.19 | -0.15 |
| Market Capitalization | 15.82 M | 19.03 B |
| Total Asset | 11.86 M | 29.47 B |
| Retained Earnings | (144.41 M) | 9.33 B |
| Working Capital | 6.29 M | 1.48 B |
| Current Asset | 1.53 M | 9.34 B |
Note: Acquisition by Spandow Oliver J. of 7062 shares of Nephros at 6.82 subject to Rule 16b-3 [view details]
Nephros Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nephros . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 1582.15 | |||
| Daily Balance Of Power | 0.125 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 1.52 | |||
| Day Typical Price | 1.52 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | 0.01 |
About Nephros Buy or Sell Advice
When is the right time to buy or sell Nephros? Buying financial instruments such as Nephros Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nephros in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sector ETFs Thematic Idea Now
Sector ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sector ETFs theme has 440 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sector ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Nephros Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share 1.313 | Quarterly Revenue Growth (0.08) | Return On Assets (0.08) | Return On Equity (0.16) |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.